» Articles » PMID: 30873373

Rare Complication of Botox Injection: A Case Report

Overview
Specialty General Surgery
Date 2019 Mar 16
PMID 30873373
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Botulinum toxin (BTX) is also well-known as Botox is produced by a gram-positive anaerobic bacterium called Generally, clinical manifestations of BTX can be observed after consumption of contaminated food, from colonization of the infant gastrointestinal tract, as well as following the infection of the wound to this bacterium. There are seven types of this neurotoxin labeled as A, B, C (C1, C2), D, E, and F. Human botulinum is caused by types A, B, E and rarely F. The most common clinical symptoms of BTX in cosmetic goals are cervical dystonia, severe primary axillary hyperhidrosis, strabismus, neurogenic detrusor over-activity, chronic migraine, upper limb spasticity and blepharospasm. Botox has a wide range of therapeutic uses and occasionally patients receiving this treatment may experience botulism symptom including local and even distant and autonomic symptoms. Despite the efficacies of Botox in treatment of myriad neurologic and cosmetic conditions, it may carry some risk of sever adverse effects which may be the result of local or systemic spreading of the drug. Our patient was a 22 years old man who received Botox for axillary hyperhidrosis after two weeks, when most of generalized complications of botulinum toxin appeared. This case was introduced for being aware of dangerous complication of Botox. Pyridostigmine could relieve symptoms of the patient.

Citing Articles

From Botox Party to Botulism: A Case Report and Public Health Warning on Adulterated Botulinum Toxin Injection.

Dawson E, Pateriya S, Blashinsky Z, Landa-Galindez A Cureus. 2024; 16(8):e68016.

PMID: 39211826 PMC: 11361325. DOI: 10.7759/cureus.68016.


Self-Administered Botulinum Injection Causing Rare Masquerade of Systemic Botulism.

Tay K, Ong A, Tay W, Juan S, Chua K Cureus. 2024; 16(7):e64976.

PMID: 39161519 PMC: 11331558. DOI: 10.7759/cureus.64976.


A severe case of iatrogenic botulism associated with COVID-19 infection.

Ma Q, Liu G, Wang S, Wang W, Liu N, Wang C Heliyon. 2024; 10(11):e32237.

PMID: 38933984 PMC: 11200343. DOI: 10.1016/j.heliyon.2024.e32237.


The efficacy and safety of a fractional microneedle radiofrequency device for the treatment of axillary hyperhidrosis: clinical prospective pilot study.

Jung J, Na H, Kim J, Yoon J, Yang H, Lee W Lasers Med Sci. 2021; 37(3):1559-1566.

PMID: 34453655 DOI: 10.1007/s10103-021-03404-z.

References
1.
de Paiva A, Meunier F, Molgo J, Aoki K, Dolly J . Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999; 96(6):3200-5. PMC: 15919. DOI: 10.1073/pnas.96.6.3200. View

2.
Erbguth F, Naumann M . Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology. 1999; 53(8):1850-3. DOI: 10.1212/wnl.53.8.1850. View

3.
Maselli R, Bakshi N . AAEM case report 16. Botulism. American Association of Electrodiagnostic Medicine. Muscle Nerve. 2000; 23(7):1137-44. DOI: 10.1002/1097-4598(200007)23:7<1137::aid-mus21>3.0.co;2-7. View

4.
Barr J, Moura H, Boyer A, Woolfitt A, Kalb S, Pavlopoulos A . Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis. 2005; 11(10):1578-83. PMC: 3366733. DOI: 10.3201/eid1110.041279. View

5.
Wohlfarth K, Schwandt I, Wegner F, Jurgens T, Gelbrich G, Wagner A . Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol. 2008; 255(12):1932-9. DOI: 10.1007/s00415-008-0031-7. View